Athersys (ATHX) Earning Somewhat Favorable Press Coverage, Study Finds

Media headlines about Athersys (NASDAQ:ATHX) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research group ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Athersys earned a news sentiment score of 0.17 on Accern’s scale. Accern also assigned news articles about the biopharmaceutical company an impact score of 44.797016831709 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Shares of Athersys (NASDAQ ATHX) traded down $0.08 during mid-day trading on Friday, hitting $1.78. 971,767 shares of the stock traded hands, compared to its average volume of 557,680. Athersys has a 12-month low of $1.02 and a 12-month high of $2.63.

ATHX has been the topic of several recent analyst reports. Maxim Group restated a “buy” rating and set a $12.00 price objective on shares of Athersys in a research report on Friday, September 1st. Zacks Investment Research upgraded shares of Athersys from a “hold” rating to a “buy” rating and set a $2.00 price objective on the stock in a research report on Tuesday, August 29th. Finally, ValuEngine upgraded shares of Athersys from a “sell” rating to a “hold” rating in a research report on Wednesday, November 22nd. One analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $7.17.

In related news, EVP John J. Harrington sold 15,000 shares of the firm’s stock in a transaction on Monday, September 18th. The shares were sold at an average price of $2.17, for a total transaction of $32,550.00. Following the completion of the transaction, the executive vice president now directly owns 679,416 shares of the company’s stock, valued at $1,474,332.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 9.40% of the stock is owned by company insiders.

TRADEMARK VIOLATION NOTICE: This story was first published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this story on another site, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark laws. The original version of this story can be read at

About Athersys

Athersys, Inc is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients.

Insider Buying and Selling by Quarter for Athersys (NASDAQ:ATHX)

Receive News & Ratings for Athersys Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply